Literature DB >> 30257988

Targeting of SGK1 by miR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion.

Evan J Greenawalt1, Mick D Edmonds2, Neha Jain3, Clare M Adams1, Ramkrishna Mitra1, Christine M Eischen4.   

Abstract

Metastatic lung cancer is common in patients with lung adenocarcinoma, but the molecular mechanisms of metastasis remain incompletely resolved. miRNA regulate gene expression and contribute to cancer development and progression. This report identifies miR-576-3p and its mechanism of action in lung cancer progression. miR-576-3p was determined to be significantly decreased in clinical specimens of late-stage lung adenocarcinoma. Overexpression of miR-576-3p in lung adenocarcinoma cells decreased mesenchymal marker expression and inhibited migration and invasion. Inhibition of miR-576-3p in nonmalignant lung epithelial cells increased migration and invasion as well as mesenchymal markers. Serum/glucocorticoid-regulated kinase 1 (SGK1) was a direct target of miR-576-3p, and modulation of miR-576-3p levels led to alterations in SGK1 protein and mRNA as well as changes in activation of its downstream target linked to metastasis, N-myc downstream regulated 1 (NDRG1). Loss of the ability of miR-576-3p to bind the 3'-UTR of SGK1 rescued the inhibition in migration and invasion observed with miR-576-3p overexpression. In addition, increased SGK1 levels were detected in lung adenocarcinoma patient samples expressing mesenchymal markers, and pharmacologic inhibition of SGK1 resulted in a similar inhibition of migration and invasion of lung adenocarcinoma cells as observed with miR-576-3p overexpression. Together, these results reveal miR-576-3p downregulation is selected for in late-stage lung adenocarcinoma due to its ability to inhibit migration and invasion by targeting SGK1. Furthermore, these results also support targeting SGK1 as a potential therapeutic for lung adenocarcinoma. IMPLICATIONS: This study reveals SGK1 inhibition with miR-576-3p or pharmacologically inhibits migration and invasion of lung adenocarcinoma, providing mechanistic insights into late-stage lung adenocarcinoma and a potential new treatment avenue. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30257988      PMCID: PMC6318035          DOI: 10.1158/1541-7786.MCR-18-0364

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.

Authors:  P Wang; T Lushnikova; J Odvody; T C Greiner; S N Jones; C M Eischen
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

2.  MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.

Authors:  Mick D Edmonds; Kelli L Boyd; Tamara Moyo; Ramkrishna Mitra; Robert Duszynski; Maria Pia Arrate; Xi Chen; Zhongming Zhao; Timothy S Blackwell; Thomas Andl; Christine M Eischen
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

3.  EMT in cancer.

Authors:  Thomas Brabletz; Raghu Kalluri; M Angela Nieto; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

4.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

5.  p53-mediated activation of miRNA34 candidate tumor-suppressor genes.

Authors:  Guido T Bommer; Isabelle Gerin; Ying Feng; Andrew J Kaczorowski; Rork Kuick; Robert E Love; Yali Zhai; Thomas J Giordano; Zhaohui S Qin; Bethany B Moore; Ormond A MacDougald; Kathleen R Cho; Eric R Fearon
Journal:  Curr Biol       Date:  2007-07-26       Impact factor: 10.834

6.  Therapeutic inhibition of SGK1 suppresses colorectal cancer.

Authors:  Xuchun Liang; Chunling Lan; Guanming Jiao; Wencheng Fu; Xuesha Long; Yu An; Kejin Wang; Jinzhe Zhou; Ting Chen; Yongqin Li; Jiahong Xu; Qi Huang; Bin Xu; Junjie Xiao
Journal:  Exp Mol Med       Date:  2017-11-24       Impact factor: 8.718

7.  Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.

Authors:  Z-M Shi; L Wang; H Shen; C-F Jiang; X Ge; D-M Li; Y-Y Wen; H-R Sun; M-H Pan; W Li; Y-Q Shu; L-Z Liu; S C Peiper; J He; B-H Jiang
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

Review 8.  The role of MicroRNAs in human cancer.

Authors:  Yong Peng; Carlo M Croce
Journal:  Signal Transduct Target Ther       Date:  2016-01-28

9.  miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.

Authors:  Laura Y McGirt; Clare M Adams; Devin A Baerenwald; Jeffrey P Zwerner; John A Zic; Christine M Eischen
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

10.  PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

Authors:  Pau Castel; Haley Ellis; Ruzica Bago; Eneda Toska; Pedram Razavi; F Javier Carmona; Srinivasaraghavan Kannan; Chandra S Verma; Maura Dickler; Sarat Chandarlapaty; Edi Brogi; Dario R Alessi; José Baselga; Maurizio Scaltriti
Journal:  Cancer Cell       Date:  2016-07-21       Impact factor: 31.743

View more
  18 in total

1.  circDNMT1 Promotes Malignant Progression of Gastric Cancer Through Targeting miR-576-3p/Hypoxia Inducible Factor-1 Alpha Axis.

Authors:  Hanghang Li; Bo Cao; Ruiyang Zhao; Tian Li; Xingming Xu; Hao Cui; Huan Deng; Jingwang Gao; Bo Wei
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  MiR-139-5p Targeting CCNB1 Modulates Proliferation, Migration, Invasion and Cell Cycle in Lung Adenocarcinoma.

Authors:  Bin Bao; Xiaojun Yu; Wujun Zheng
Journal:  Mol Biotechnol       Date:  2022-02-18       Impact factor: 2.860

3.  MiR-486-5p specifically suppresses SAPCD2 expression, which attenuates the aggressive phenotypes of lung adenocarcinoma cells.

Authors:  Desheng Wei
Journal:  Histol Histopathol       Date:  2022-04-25       Impact factor: 2.130

Review 4.  The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star.

Authors:  Ruizhe Zhu; Gang Yang; Zhe Cao; Kexin Shen; Lianfang Zheng; Jianchun Xiao; Lei You; Taiping Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-07-15       Impact factor: 8.168

5.  Genome-Wide Analysis of Lung Adenocarcinoma Identifies Novel Prognostic Factors and a Prognostic Score.

Authors:  Donglai Chen; Yueqiang Song; Fuquan Zhang; Xiaofan Wang; Erjia Zhu; Xi Zhang; Gening Jiang; Siguang Li; Chang Chen; Yongbing Chen
Journal:  Front Genet       Date:  2019-05-22       Impact factor: 4.599

6.  HDAC2 interacts with microRNA-503-5p to regulate SGK1 in osteoarthritis.

Authors:  Zheng Wang; Nan Zhou; Wengang Wang; Yangke Yu; Lei Xia; Ning Li
Journal:  Arthritis Res Ther       Date:  2021-03-09       Impact factor: 5.156

7.  Identification of the pyroptosis‑related prognostic gene signature and the associated regulation axis in lung adenocarcinoma.

Authors:  Wanli Lin; Ying Chen; Bomeng Wu; Ying Chen; Zuwei Li
Journal:  Cell Death Discov       Date:  2021-06-25

8.  Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival.

Authors:  Ramkrishna Mitra; Clare M Adams; Wei Jiang; Evan Greenawalt; Christine M Eischen
Journal:  Nat Commun       Date:  2020-02-20       Impact factor: 14.919

9.  Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs.

Authors:  Douâa Moussa Agha; Redouane Rouas; Mehdi Najar; Fatima Bouhtit; Najib Naamane; Hussein Fayyad-Kazan; Dominique Bron; Nathalie Meuleman; Philippe Lewalle; Makram Merimi
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

10.  ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.

Authors:  Zhuoyu Gu; Liping Wang; Xiaohan Yao; Qian Long; Kaping Lee; Jieyao Li; Dongli Yue; Shuangning Yang; Yanfen Liu; Na Li; Yixin Li
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.